Neurodegenerative Disease ResearchInc (EIN 850520661) - Form 990 Financial Analysis & Trantor Score

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

2020

Legal Domicile

Principal Officer

Siobhan Ellison

Phone

3522145209

Tax Period

2024-01-01 to 2024-12-31

Neurodegenerative Disease ResearchInc, founded in 2020, is a community nonprofit in the Medical Research sector that reported $1.6M in total revenue in fiscal year 2024. Revenue decreased 14% compared to the prior year.

Mission

Our goal is to facilitate research that will bring new treatments to those suffering from neurodegenerative diseases. We fund researchers that have projects intended to bring new hope to ALS patients.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2024)

Revenue Breakdown

Contributions & Grants $1,561,118

Program Service Revenue $0

Investment Income $0

Other Revenue $0

TOTAL REVENUE $1,561,118

Expense Breakdown

Grants Paid $742,929

Salaries & Benefits $161,487

Fundraising Expenses $3,493

Program Expenses $1,511,994

Other Expenses $635,806

TOTAL EXPENSES $1,540,222

Year-over-Year Comparison

	2024	2023	Change
Revenue	$1,561,118	$1,814,325	-0.1%
Expenses	$1,540,222	$2,138,891	-0.3%
Net Income	$20,896	$-324,566	-1.1%

Key Indicators

✓ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✓ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

N/A

Volunteers

Governance Policies

✗ Conflict of Interest Policy

✗ Whistleblower Policy

✗ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

⚠ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

$150,000

Total Directors

$150,000

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
Siobhan Ellison	President and CEO	40.00	Officer Director	$150,000	$0	$150,000
Julie Osborne	Board Member	6.00	Director	$0	$0	$0
Bill Killeen	Vice President	6.00	Officer Director	$0	$0	$0

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2024	$1,561,118	$1,540,222	$248,396	$20,896
2023	$1,814,325	$2,138,891	$227,525	$-324,566
2022	$4,274,249	$4,380,443	$563,346	$-106,194
2021	$3,928,115	$4,384,392	$603,568	$-456,277
2020	$3,250,647	$2,190,895	$1,063,188	$1,059,752

Neurodegenerative Disease ResearchInc